Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Quinn

Showing results (21-30 of 255) with videos related to

Pageof 26
Sort By:
The Journal of Urology|October 30, 2019
Editorial CommentAnishka A D'Souza, David I Quinn
Journal of the American Dental Association (1939)|October 1, 1979
Amelogenesis imperfecta: local hypoplastic type with pulpal calcificationG B Gertzman, G Gaston, I Quinn
Journal of Dental Education|July 1, 1971
A report of the department of removable prosthodontics during the first decadeI Quinn, P W Vinton, D DuVall
Clinical Prostate Cancer|January 8, 2005
Angiogenesis-targeted therapies in prostate cancerPrimo N Lara, Przemyslaw Twardowski, David I Quinn
Clinical Pharmacokinetics|December 10, 1997
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug usersD I Quinn, A Wodak, R O Day
Urologic Oncology|June 22, 2015
Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful storyTanya B Dorff, James Hu, David I Quinn
Therapeutic Advances in Medical Oncology|July 27, 2011
Targeted therapy in renal cancerTanya B Dorff, Amir Goldkorn, David I Quinn
Radiology|January 28, 2015
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastasesHossein Jadvar, Susan G Groshen, David I Quinn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2013
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shoreA Goldkorn, A M Aparicio, D I Quinn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directionsM B Atkins, J I Clark, D I Quinn
Pageof 26

Showing results (21-30 of 255) with videos related to

Sort By:
Pageof 26
The Journal of Urology|October 30, 2019
Editorial CommentAnishka A D'Souza, David I Quinn
Journal of the American Dental Association (1939)|October 1, 1979
Amelogenesis imperfecta: local hypoplastic type with pulpal calcificationG B Gertzman, G Gaston, I Quinn
Journal of Dental Education|July 1, 1971
A report of the department of removable prosthodontics during the first decadeI Quinn, P W Vinton, D DuVall
Clinical Prostate Cancer|January 8, 2005
Angiogenesis-targeted therapies in prostate cancerPrimo N Lara, Przemyslaw Twardowski, David I Quinn
Clinical Pharmacokinetics|December 10, 1997
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug usersD I Quinn, A Wodak, R O Day
Urologic Oncology|June 22, 2015
Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful storyTanya B Dorff, James Hu, David I Quinn
Therapeutic Advances in Medical Oncology|July 27, 2011
Targeted therapy in renal cancerTanya B Dorff, Amir Goldkorn, David I Quinn
Radiology|January 28, 2015
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastasesHossein Jadvar, Susan G Groshen, David I Quinn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2013
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shoreA Goldkorn, A M Aparicio, D I Quinn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directionsM B Atkins, J I Clark, D I Quinn
Pageof 26